-
Pricing per bottle is $695.65! Lilly AD New Drug Approved for Market, Encountering Strong Competitors with Lencamab
21st Century Business Herald reporter Han Liming reports from Shanghai On July 2nd local time, Lilly (NYSE: LLY) announced that Kisunla (donanemab, 350 mg/20 mL) has been approved by the US FDA for t ... -
Eli Lilly AD new drug approved for market launch, lencamab meets strong competitors
On July 2nd local time, Lilly (NYSE: LLY) announced that Kisunla (donanemab, 350mg/20mL) has been approved by the US FDA for the treatment of early-stage symptoms of Alzheimer's disease (AD), includi ... -
The Class 1 new drug introduced by Anjin with over 1 billion US dollars has been approved for clinical use
New Beijing News (Reporter Zhang Zhaohui) On September 4th, the official website of the National Medical Products Administration announced that a new clinical application for Amgen's Class 1 new drug ...